MA micro automation GmbH, a subsidiary of MAX Automation SE, receives major order from the medical technology sector

DGAP-News: MAX Automation SE / Key word(s): Incoming Orders
09.12.2019 / 07:30
The issuer is solely responsible for the content of this announcement.


MA micro automation GmbH, a subsidiary of MAX Automation SE, receives major order from the medical technology sector

Duesseldorf, 9 December 2019 - MA micro automation GmbH (MA micro), a subsidiary of MAX Automation SE, listed in the Prime Standard of the German Stock Exchange, announces a new major order. For a customer in the medical technology sector, the special machine builder will build assembly machines for medical optical systems. The order from the USA has a total volume in the low double-digit million Euro range.

The company based in St. Leon-Rot near Heidelberg with more than 170 employees is one of the leading international companies for automation solutions and special machine construction in the fields of medical technology and opto-electronic components. MA micro supplies the medical technology industry with production, testing and assembly systems for medical devices like contact lenses, diagnostic consumables, medical injection moulding components, inhalers, insulin pens, auto injectors as well as tips and cups.

The current major order is a further proof of the successful transformation process of MA micro - which is part of the Evolving Technologies business unit - towards the future market of medical technology and internationalization. "In 2013 the company was taken over by MAX Automation SE. Shortly afterwards, the strategic decision was made to focus the special machine manufacturer's activities on the field of medical technology. Now it is clear how successful and sustainable this strategy is, the new major order confirms that we will continue along this path", explains Dr. Guido Hild, head of the Evolving Technologies business unit and member of the Management Board of MAX Automation SE.

With its focus on medical technology, MA micro is active in a sustainably growing segment. Under the umbrella term "Lifescience", this area builds on global megatrends such as population growth and increasingly higher life expectancy. MA micro is ideally positioned here with its locations in Europe, Asia (Singapore) and North America (USA). It has a stable customer base. The demand for products covered by MA micro is growing dynamically. Due to its positioning, the company is optimistic about winning further major orders.

More information about MA micro automation can be found here:



Katja Redweik
Head of Corporate Development/IR
MAX Automation SE
Tel.: +49 - 211 - 9099 144

Contact for media representatives:

Susan Hoffmeister     Marco Cabras
CROSS ALLIANCE communication GmbH     newskontor - Agentur für Kommunikation
Phone: +49 - 89 - 125 09 03 33     Phone: +49 - 211 - 863 949 22

About MAX Automation SE
MAX Automation SE (ISIN DE000A2DA58), based in Dusseldorf, Germany, is an internationally active industrial group for high-tech automation solutions. The Group's operating business is divided into three segments: in its Process Technologies segment, the Group's comprehensive technological know-how makes it an innovation leader in the development and manufacture of proprietary solutions (e.g. dosing, impregnation), particularly for the automotive and electronics industries. MAX Automation's Environmental Technologies segment develops and installs technologically complex plants for the recycling, energy and raw materials industries. In its Evolving Technologies segment, MAX Automation bundles companies with growth potential in the fields of optical solutions, solutions for medical technology, industrial robotics and automation, as well as packaging solutions.

09.12.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at

show this
This website uses cookies. Please see our privacy guidelines for further details.